Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Current Trends in the Treatment of CRC

February 26th 2014

Tumor Profiling in Patients With mCRC

February 26th 2014

New Therapies in Development for mCRC

February 26th 2014

Role of the VEGF Inhibitor Aflibercept in mCRC

February 26th 2014

Role of the Multikinase Inhibitor Regorafenib in mCRC

February 26th 2014

Considerations When Selecting an EGFR Inhibitor in mCRC

February 26th 2014

First- and Later-line Use of Panitumumab in mCRC

February 26th 2014

Treatment of Unresectable RAS Wild-type Metastatic CRC

February 26th 2014

Upfront Bevacizumab and Cetuximab Compared in mCRC

February 26th 2014

Clinical Development of Cetuximab in mCRC

February 26th 2014

Optimizing Treatment With EGFR Inhibitors in CRC

February 26th 2014

Introduction: Expanded RAS Testing in Colorectal Cancer

February 26th 2014

Minimally Invasive Techniques Make Strides in Liver Surgery

February 25th 2014

During the past 15 years, minimally invasive general surgery has rapidly expanded to include laparoscopic and robotic techniques for cholecystectomy, colectomy, gastric weight loss, and other procedures

Dr. Fakih on Angiogenesis Versus EGFR Inhibitors in CRC

February 25th 2014

Marwan G. Fakih, MD, professor, director, Gastrointestinal Medical Oncology, City of Hope, discusses anti-angiogenesis versus anti-EGFR therapy in patients who have RAS wild-type colorectal cancer.

Dr. Bendell on using OMP-59R5 to treat Pancreatic Cancer

February 21st 2014

Johanna Bendell, MD, director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses the anti-cancer stem cell antibody OMP-59R5 as a treatment option for patients with metastatic pancreatic cancer.

Dr. Fuchs on Angiogenesis in Gastric Cancer

February 20th 2014

Charles S. Fuchs, MD, MPH, director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, discusses targeting angiogenesis in the treatment of gastric cancer.

Dr. Abou-Alfa Discusses CRP in HCC

February 18th 2014

Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses a retrospective study to determine the prognostic value of C-reactive protein (CRP) levels in patients with hepatocellular carcinoma (HCC) who are undergoing sorafenib treatment

New Drug Development Needed in Pancreatic Cancer

February 11th 2014

Case Study: Treatment of Metastatic Pancreatic Cancer

February 11th 2014

Emerging Therapies and Novel Targets in Pancreatic Cancer

February 11th 2014